ATE496909T1 - Substituierte amide, herstellungsverfahren und verwendungsverfahren - Google Patents

Substituierte amide, herstellungsverfahren und verwendungsverfahren

Info

Publication number
ATE496909T1
ATE496909T1 AT07842267T AT07842267T ATE496909T1 AT E496909 T1 ATE496909 T1 AT E496909T1 AT 07842267 T AT07842267 T AT 07842267T AT 07842267 T AT07842267 T AT 07842267T AT E496909 T1 ATE496909 T1 AT E496909T1
Authority
AT
Austria
Prior art keywords
methods
production process
substituted amides
amides
substituted
Prior art date
Application number
AT07842267T
Other languages
English (en)
Inventor
Peter A Blomgren
Seung H Lee
Scott A Mitchell
Jianjun Xu
Aaron C Schmitt
Original Assignee
Cgi Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39184519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE496909(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cgi Pharmaceuticals Inc filed Critical Cgi Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE496909T1 publication Critical patent/ATE496909T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT07842267T 2006-09-11 2007-09-11 Substituierte amide, herstellungsverfahren und verwendungsverfahren ATE496909T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84383306P 2006-09-11 2006-09-11
PCT/US2007/078185 WO2008033857A2 (en) 2006-09-11 2007-09-11 Substituted amides, method of making, and method of use thereof

Publications (1)

Publication Number Publication Date
ATE496909T1 true ATE496909T1 (de) 2011-02-15

Family

ID=39184519

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07842267T ATE496909T1 (de) 2006-09-11 2007-09-11 Substituierte amide, herstellungsverfahren und verwendungsverfahren

Country Status (24)

Country Link
EP (1) EP2079726B1 (de)
JP (1) JP5563301B2 (de)
KR (1) KR101444481B1 (de)
CN (1) CN101605778A (de)
AR (1) AR063707A1 (de)
AT (1) ATE496909T1 (de)
AU (1) AU2007296563B2 (de)
BR (1) BRPI0716914A2 (de)
CA (1) CA2661951C (de)
CL (1) CL2007002642A1 (de)
CO (1) CO6180464A2 (de)
CR (1) CR10709A (de)
DE (1) DE602007012281D1 (de)
EC (1) ECSP099238A (de)
ES (1) ES2363269T3 (de)
IL (1) IL197264A0 (de)
MA (1) MA31276B1 (de)
MX (1) MX2009002651A (de)
NO (1) NO20091426L (de)
PE (1) PE20081370A1 (de)
RU (1) RU2009113692A (de)
TW (1) TWI398439B (de)
WO (1) WO2008033857A2 (de)
ZA (1) ZA200901634B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080839A1 (es) * 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
ES2444144T3 (es) * 2007-10-23 2014-02-24 F. Hoffmann-La Roche Ag Nuevos inhibidores de quinasa
US7683064B2 (en) 2008-02-05 2010-03-23 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
ES2554615T3 (es) * 2008-05-06 2015-12-22 Gilead Connecticut, Inc. Amidas sustituidas, método de preparación y utilización como inhibidores de Btk
CA2728016C (en) 2008-06-24 2017-02-28 F. Hoffmann-La Roche Ag Novel substituted pyridin-2-ones and pyridazin-3-ones
AU2009265813B2 (en) 2008-07-02 2014-04-10 F. Hoffmann-La Roche Ag Novel phenylpyrazinones as kinase inhibitors
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
EP2877598A1 (de) 2012-07-24 2015-06-03 Pharmacyclics, Inc. Mutationen im zusammenhang mit der resistenz gegenüber hemmern der bruton-tyrosinkinase (btk)
MX367918B (es) 2013-04-25 2019-09-11 Beigene Ltd Compuestos heterociclicos fusionados como inhibidores de proteina quinasa.
CN104177338B (zh) * 2013-05-22 2018-04-03 南京勇山生物科技有限公司 一类布鲁顿激酶抑制剂
SI3702373T1 (sl) 2013-09-13 2022-11-30 Beigene Switzerland Gmbh Protitelesa proti PD-1 in njihova uporaba kot terapevtiki in diagnostiki
CA2929918C (en) * 2013-12-05 2018-01-23 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
KR102003754B1 (ko) 2014-07-03 2019-07-25 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
WO2016079669A1 (en) * 2014-11-19 2016-05-26 Novartis Ag Labeled amino pyrimidine derivatives
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
LT3377488T (lt) 2015-11-19 2023-01-10 Incyte Corporation Heterocikliniai junginiai, kaip imunomoduliatoriai
WO2017106634A1 (en) * 2015-12-17 2017-06-22 Incyte Corporation N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators
SI3394033T1 (sl) 2015-12-22 2021-03-31 Incyte Corporation Heterociklične spojine kot imunomodulatorji
MA44860A (fr) 2016-05-06 2019-03-13 Incyte Holdings Corp Composés hétérocycliques utilisés comme immunomodulateurs
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
MA45189A (fr) 2016-06-07 2019-04-10 Jacobio Pharmaceuticals Co Ltd Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
EP4137489A1 (de) 2016-06-20 2023-02-22 Incyte Corporation Heterocyclische verbindungen als immunmodulatoren
NZ749997A (en) 2016-07-05 2022-11-25 Beigene Ltd Combination of a pd-l antagonist and a raf inhibitor for treating cancer
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
TW202233628A (zh) 2016-08-16 2022-09-01 英屬開曼群島商百濟神州有限公司 (s)-7-(1-丙烯醯基六氫吡啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑並[1,5-a]嘧啶-3-甲醯胺的晶型、其製備和用途
ES2971881T3 (es) 2016-08-19 2024-06-10 Beigene Switzerland Gmbh Combinación de zanubrutinib con un anticuerpo anti-cd20 o anti-pd-1 para su uso en el tratamiento del cáncer
EP3504198B1 (de) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclische verbindungen als immunmodulatoren
EP3515414B1 (de) 2016-09-19 2022-11-30 MEI Pharma, Inc. Kombinationstherapie
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
MX2019007416A (es) 2016-12-22 2019-12-11 Incyte Corp Derivados de benzooxazol como inmunomoduladores.
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
TWI798192B (zh) 2016-12-22 2023-04-11 美商英塞特公司 免疫調節劑化合物及使用方法
EP3573989A4 (de) 2017-01-25 2020-11-18 Beigene, Ltd. Kristalline formen von (s)-7-(1-(but-2-ynoyl)-piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-carboxamid, herstellung und verwendungen davon
KR20220113545A (ko) 2017-03-23 2022-08-12 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
TW201906866A (zh) 2017-06-26 2019-02-16 英屬開曼群島商百濟神州有限公司 酸性鞘磷脂酶缺乏症患者中異常骨狀況的治療
WO2019034009A1 (en) 2017-08-12 2019-02-21 Beigene, Ltd. BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
ES2940750T3 (es) 2018-03-30 2023-05-11 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
HRP20230306T1 (hr) 2018-05-11 2023-05-12 Incyte Corporation Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori
CA3150434A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
TW202126652A (zh) 2019-09-30 2021-07-16 美商英塞特公司 作為免疫調節劑之吡啶并[3,2—d]嘧啶化合物
KR20220101664A (ko) 2019-11-11 2022-07-19 인사이트 코포레이션 Pd-1/pd-l1 억제제의 염 및 결정질 형태
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU768201B2 (en) * 1999-01-22 2003-12-04 Amgen, Inc. Kinase inhibitors
JP2005255675A (ja) * 2004-02-09 2005-09-22 Tanabe Seiyaku Co Ltd 医薬組成物
RU2423351C2 (ru) * 2004-12-16 2011-07-10 Вертекс Фармасьютикалз Инкорпорейтед Пирид-2-оны, применимые как ингибиторы протеинкиназ семейства тес для лечения воспалительных, пролиферативных и иммунологически-опосредованных заболеваний

Also Published As

Publication number Publication date
PE20081370A1 (es) 2008-11-28
IL197264A0 (en) 2009-12-24
WO2008033857A2 (en) 2008-03-20
RU2009113692A (ru) 2010-10-20
MX2009002651A (es) 2009-03-26
ZA200901634B (en) 2009-12-30
WO2008033857A3 (en) 2008-06-05
EP2079726A2 (de) 2009-07-22
AU2007296563B2 (en) 2013-01-10
TWI398439B (zh) 2013-06-11
MA31276B1 (fr) 2010-04-01
AR063707A1 (es) 2009-02-11
CL2007002642A1 (es) 2008-07-18
CA2661951C (en) 2014-11-18
CO6180464A2 (es) 2010-07-19
AU2007296563A1 (en) 2008-03-20
NO20091426L (no) 2009-06-10
DE602007012281D1 (de) 2011-03-10
ES2363269T3 (es) 2011-07-28
TW200829567A (en) 2008-07-16
BRPI0716914A2 (pt) 2013-11-05
KR101444481B1 (ko) 2014-09-24
JP2010502750A (ja) 2010-01-28
KR20090074192A (ko) 2009-07-06
EP2079726B1 (de) 2011-01-26
CN101605778A (zh) 2009-12-16
CR10709A (es) 2009-07-14
CA2661951A1 (en) 2008-03-20
ECSP099238A (es) 2009-07-31
JP5563301B2 (ja) 2014-07-30

Similar Documents

Publication Publication Date Title
ATE496909T1 (de) Substituierte amide, herstellungsverfahren und verwendungsverfahren
IL197230A0 (en) Certain substituted amides, method of making, and method of use thereof
IL185785A0 (en) Certain substituted amides, method of making, and method of use thereof
BRPI0922248A2 (pt) eletrodo e método de produção do mesmo
ATE514637T1 (de) Sprühvorrichtung und herstellungsverfahren dafür
EG26976A (en) Amide derivatives, process for production of the same, and method for application thereof as insecticide
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
DE602006009036D1 (de) Hängendes Bauelement und Herstellungsverfahren
IL217212A0 (en) Process for the production of amides
DE602006001238D1 (de) Filter und dessen Herstellungsmethode
BRPI0906305A2 (pt) artigo absorvente e método de produção do mesmo
ATE503751T1 (de) Substituierte benzimidazole und herstellungsverfahren dafür
DE602006013761D1 (de) Herstellungsverfahren für wasserabsorbierende Partikel und wasserabsorbierende Partikel
IL191035A0 (en) Pharmaceutical use of substituted amides
IL191034A0 (en) Pharmaceutical use of substituted amides
EP2013835A4 (de) Herstellung von chiralen amiden und aminen
DE602005019778D1 (de) Chemisches verfahren und produktionseinheit
IL188306A0 (en) Crystals of phenylalanine derives,, production method thereof and use thereof
ATE550014T1 (de) Hydrogel-suspension und herstellungsverfahren dafür
EP2245020A4 (de) Thiazolylidinharnstoff- und amidderivate und verfahren zur anwendung davon
EP1837350A4 (de) Verfahren zur herstellung von modifizierten polymeren und danach hergestellte modifizierte polymere
EP1835033A4 (de) Verfahren zur herstellung einer amidverbindung und eines acrylamidpolymers
EP2116529A4 (de) Verfahren zur herstellung eines amids oder lactams
GB2469959B (en) Dioctatin derivatives and production process thereof
ZA200708108B (en) Certain substituted amides, method of making, and method of use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties